Bernstein reaffirms Buy for Elevance Health stock

Published on 10/06/2026 at 13:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bernstein kept its USD 488.00 target on October 5, 2026. Elevance Health stock was at EUR 352.45 during trading on October 6, 2026.

Elevance Health, US0367521038, Illustration mit AI erstellt.

Elevance Health stock was trading at EUR 352.45 at Lang & Schwarz on October 6, 2026 at 1:16 p.m. CEST. On October 5, 2026, Markets Insider reported that Bernstein maintained a Buy rating and a USD 488.00 price target for Elevance Health.

Bernstein keeps the USD 488.00 target

The rating matters because the target sits above the latest primary-market quote of USD 394.51 from October 5, 2026. The target also places the analyst view above the current market value, while the stock remains below its 52-week high of USD 436.24.

The NYSE quote was USD 394.51 on October 5, 2026, with a 52-week range of USD 274.84 to USD 436.24. Market capitalization stood at USD 85.6 billion on that date, giving the insurer a large-cap profile despite the gap between its market price and the cited target.

Revenue rose in the second quarter

For the second quarter of 2026, Markets Insider reported revenue of USD 50.47 billion, compared with USD 49.78 billion in the same quarter a year earlier. That represents growth of 1.39 percent, while net profit declined from USD 1.74 billion to USD 1.46 billion, a decrease of 16.09 percent.

The contrast between revenue growth and lower net profit puts operating costs and medical spending at the center of the next earnings discussion. The same report said the company had raised its 2026 adjusted earnings-per-share guidance to at least USD 27.00.

Results are scheduled for October 21

Business Wire reported that Elevance Health will release third-quarter 2026 results on October 21, 2026, at 6:00 a.m. Eastern Daylight Time. Management is scheduled to discuss the results and outlook at 8:30 a.m. Eastern Daylight Time.

That date gives investors a defined checkpoint for testing the USD 27.00 adjusted earnings-per-share outlook against medical-cost trends and the profit decline reported for the second quarter.

EUR 352.45 in the German session

Elevance Health was trading at EUR 352.45 at Lang & Schwarz on October 6, 2026 at 1:16 p.m. CEST. The US quote was USD 394.51 on October 5, 2026, while the 52-week high stood at USD 436.24.

The further course of trading is shown by the continuously updated real-time quote of Elevance Health stock.